Physician profile
Donald Negroski
NPI 1073624102
$1,377,815.61
in general payments reported to CMS, 2019-2025
56 companies · $236K in 2025
The $236K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275K · 2020: $164K · 2021: $156K · 2022: $142K · 2023: $141K · 2024: $265K · 2025: $236K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $465K · Consulting Fee: $105K · Travel and Lodging: $59K · Food and Beverage: $12K · Education: $16.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $465,489.70 |
| Consulting Fee | $105,144.50 |
| Travel and Lodging | $58,511.69 |
| Food and Beverage | $11,911.77 |
| Education | $16.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $691,396.29 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Biogen, INC. | $276,275.70 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Genzyme Corporation | $103,459.35 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $76,152.05 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $38,822.35 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Tg Therapeutics, INC. | $35,328.45 | 2021-2025 | |
| Merck Healthcare Kgaa | $30,315.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $28,526.32 | 2019-2025 | |
| Ares Trading Sa | $23,758.37 | 2024 | |
| Celgene Corporation | $20,680.26 | 2019-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $15,576.77 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $12,447.45 | 2024-2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $9,267.98 | 2020-2023 | Ponvory |
| Janssen Global Services, LLC | $5,004.99 | 2019 | |
| Merck Kgaa | $3,360.00 | 2024 |
Show all 55 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Negroski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.